Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome

Clinical Nephrology

Volumn 85, Issue 6, 2016, Pages 340-345

  Fujinaga, Shuichiro ^a   Ozawa, Kanako ^a   Sakuraya, Koji ^a   Yamada, Akifumi ^a   Shimizu, Toshiaki ^b  

^a SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYCLOSPORIN; DIPHENHYDRAMINE; MYCOPHENOLATE MOFETIL; PARACETAMOL; PREDNISOLONE; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CHILD; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NEPHROTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; RELAPSE; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; STEROID DEPENDENT NEPHROTIC SYNDROME; TREATMENT OUTCOME; ADOLESCENT; AGAMMAGLOBULINEMIA; CHEMICALLY INDUCED; FEMALE; MALE; PRESCHOOL CHILD; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; AGAMMAGLOBULINEMIA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROTIC SYNDROME; NEUTROPENIA; PREDNISOLONE; RETROSPECTIVE STUDIES; RITUXIMAB; TIME FACTORS; YOUNG ADULT;

EID: 84975471715     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN108835     Document Type: Article

References (17)

1. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009; 24: 1321-1328. CrossRef PubMed
2. Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T, Kaneko K. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after longterm cyclosporine. Pediatr Nephrol. 2010; 25: 539-544. CrossRef PubMed
3. Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011; 26: 1823-1828. CrossRef PubMed
4. Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol. 2013; 28: 257-264. CrossRef PubMed
5. Fujinaga S, Sakuraya K, Yamada A, Urushihara Y, Ohtomo Y, Shimizu T. Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2015; 30: 687-691. CrossRef PubMed
6. Fujinaga S, Someya T, Watanabe T, Ito A, Ohtomo Y, Shimizu T, Kaneko K. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. Eur J Pediatr. 2013; 172: 513-518. CrossRef PubMed
7. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y; Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhoodonset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014; 384: 1273-1281. CrossRef PubMed
8. Dunleavy K, Tay K, Wilson WH. Rituximab-associated neutropenia. Semin Hematol. 2010; 47: 180-186. CrossRef PubMed
9. Kamei K, Takahashi M, Fuyama M, Saida K, Machida H, Sato M, Ogura M, Ito S. Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transplant. 2015; 30: 91-96. CrossRef PubMed
10. Kshirsagar AA, Reid CJ, Alamelu J, Sinha MD. An unusual cause of severe persistent neutropenia in a child with nephrotic syndrome. BMJ Case Rep. 2013; 2013: 1-3. CrossRef PubMed
11. Trujillo JE, Bosque M, Asensio O, Ranera A, Rojo JC, Vilella M, Guijarro E, Domingo X, Valdesoiro L, Larramona H. PD42-Is rituximab a trigger for persistent hypogammaglobulinemia in idiopathic nephrotic syndrome? Clin Transl Allergy. 2014; 28: 4.
12. Besada E, Koldingsnes W, Nossent JC. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology (Oxford). 2014; 53: 1818-1824. CrossRef PubMed
13. Irie E, Shirota Y, Suzuki C, Tajima Y, Ishizawa K, Kameoka J, Harigae H, Ishii T. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol. 2010; 91: 501-508. CrossRef PubMed
14. International Study of Kidney Disease in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978; 13: 159-165. CrossRef PubMed
15. Dale DC, Fauci AS, Guerry D IV, WolffSM. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest. 1975; 56: 808-813. CrossRef PubMed
16. Delbe-Bertin L, Aoun B, Tudorache E, Lapillone H, Ulinski T. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome? Pediatr Nephrol. 2013; 28: 447-451. CrossRef PubMed
17. Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015; 57: 60-65. CrossRef PubMed